Peptide · Fact sheet
CJC-1295
Also known as CJC-1295 DAC
CJC-1295 is an experimental growth-hormone-pathway peptide, not an FDA-approved medicine. Online names may refer to different molecules or formulations, making claims especially hard to interpret.
What is CJC-1295?
CJC-1295 is a synthetic analog designed to extend growth hormone-releasing hormone signaling.
The term is used inconsistently online, including products described as with or without a drug-affinity complex (DAC). Evidence about one form should not be silently transferred to another.
Benefits people look for
It is promoted online for body composition, recovery, sleep, or anti-aging.
Those promotional claims extend well beyond the small human research base.
What the evidence supports
- Early studies observed changes in growth hormone and IGF-1 measures.
- Changes in a laboratory marker are not proof of improved recovery, muscle growth, sleep, or longevity.
All research areas
- Growth hormone and IGF-1 levels
- Pharmacology and tolerability
- Growth-hormone-pathway effects in early studies
Anecdotal reports & lived experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens.
A commonly confused product name in sleep reports
A person reported easier sleep but unwanted daytime sleepiness while using ipamorelin with a product labeled CJC-1295 without DAC.
This report concerns the no-DAC label and a second peptide. It must not be transferred to long-acting CJC-1295 or used to infer its safety or effectiveness.
Read the product-labeling example ↗Side effects & risks
- FDA cites risks including immune reactions, peptide impurities, increased heart rate, and systemic vasodilatory reactions.
- Human safety data are limited, especially for long-term or repeated use.
- Unapproved products can add purity, strength, sterility, and labeling risks.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research: how strong is it?
Early human evidenceSmall early human studies examined hormone levels and tolerability. They do not establish broad clinical benefits for popular consumer goals.
Selected research to read
Registry record for a CJC-1295 study in HIV patients with visceral obesity.
Early human study of CJC-1295 pharmacology and hormone markers.
Human study reporting effects on growth-hormone pulsatility and IGF-1.
FDA approval & research status
CJC-1295 is not FDA approved. FDA has identified limited clinical data and potential safety risks related to compounded products containing CJC-1295.
No FDA-approved use is documented in the records summarized on this page.
Early program stopped without approval
A Phase 2 CJC-1295 study in HIV-associated visceral obesity was terminated, and FDA has not approved a CJC-1295 product. The current public record does not show an active approval path.
This summarizes the cited product or research record. Trial phases do not establish successful completion of earlier stages, and a stopped program is not ongoing development. Approval applies only to the labeled product, use and population.
What we still don’t know
- Long-term human safety
- Whether biomarker changes lead to meaningful health outcomes
- How product variants differ in exposure and risk
- Interactions and risks in people with common chronic conditions
The takeaway
CJC-1295 has a biological rationale and limited early human data, but no FDA-approved use and no strong evidence for the broad benefits commonly advertised online.
Sources & further reading
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- 1fdaFDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2clinical trialsClinicalTrials.gov: CJC-1295 in HIV visceral obesity
Registry record for a CJC-1295 study in HIV patients with visceral obesity.
- 3pubmedCJC-1295 growth hormone and IGF-1 study
Early human study of CJC-1295 pharmacology and hormone markers.
- 4pubmedCJC-1295 pulsatile growth hormone study
Human study reporting effects on growth-hormone pulsatility and IGF-1.